Resources and insights

ALBUQUERQUE, NEW MEXICO EquiSeq announced today that a group of twenty countries in Europe have issued a patent on EquiSeq’s DNA test for three genetic variants that predispose to muscle disease. The tests are part of EquiSeq’s current DNA panel. Test results allow horse owners to better manage affected horses, and can be used to improve a breeding program to reduce the incidence of muscle disease. The following European countries have issued the patent: Austria, Belgium, Bulgaria, Germany, Denmark, Estonia, Finland, France, Italy, Ireland, Lithuania, Luxemburg, Latvia, Malta, The Netherlands, Portugal, Romania, Sweden, Slovenia and United Kingdom. The patent for EquiSeq’s DNA test has now been issued in 23 countries. The same patent remains pending before patent examiners in Australia and the United States. A second patent is pending in all the same countries. Generatio GmbH performs EquiSeq’s DNA tests for the European Union and United Kingdom, while EquiSeq performs genetic testing for horse owners in the United States and the rest of the world outside of the EU and UK.

Jeremy Edwards, Chair of Department of Chemistry and Chemical Biology at the University of New Mexico, is one of UNM’s most prolific inventors. Dr. Edwards is part of the EquiSeq science team and is an inventor on two of EquiSeq’s patents. In this interview, Dr. Edwards talks about the importance of protecting intellectual property.

ALBUQUERQUE, NEW MEXICO EquiSeq announced today that South Africa has issued a patent on EquiSeq’s DNA tests for three genetic variants in horses that predispose to muscle disease. The tests are part of EquiSeq’s current DNA panel. Test results allow horse owners to better manage affected horses, and can be used to improve a breeding program to reduce the incidence of muscle disease. This is the third patent issued to EquiSeq. The same patent remains pending before patent examiners in Australia, the European Union, and the United States. A second patent is pending in the same countries. Generatio GmbH performs EquiSeq’s DNA tests for the European Union and United Kingdom, while EquiSeq performs genetic testing for horse owners in the United States and the rest of the world outside of the EU and UK.

ALBUQUERQUE, NEW MEXICO EquiSeq announced today that New Zealand has issued a patent on EquiSeq’s DNA tests for three genetic variants in horses that predispose to muscle disease. The tests are part of EquiSeq’s current DNA panel. Test results allow horse owners to better manage affected horses, and can be used to improve a breeding program to reduce the incidence of muscle disease. This is the second patent issued to EquiSeq. The same patent remains pending before patent examiners in Australia, South Africa, the European Union, and the United States. A second patent is pending in the same countries. Generatio GmbH performs EquiSeq’s DNA tests for the European Union and United Kingdom, while EquiSeq performs genetic testing for horse owners in the United States and the rest of the world outside of the EU and UK.

ALBUQUERQUE, NEW MEXICO EquiSeq announced today that Canada has issued a patent on EquiSeq’s DNA tests for three genetic variants in horses that predispose to muscle disease. The tests are part of EquiSeq’s current DNA panel. Test results allow horse owners to better manage affected horses, and can be used to improve a breeding program to reduce the incidence of muscle disease. This is the first patent issued to EquiSeq. The same patent remains pending before patent examiners in Australia, New Zealand, South Africa, the European Union, and the United States. A second patent is pending in the same countries. Generatio GmbH performs EquiSeq’s DNA tests for the European Union and United Kingdom, while EquiSeq performs genetic testing for horse owners in the United States and the rest of the world outside of the EU and UK.